SG3 Management’s Vir Biotechnology VIR Stock Holding History

SG3 Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-81,500	Closed	-$3.55M	–	1312
2021 Q3	$3.55M	Buy	+81,500	New	+$3.53M	0.11%	189

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

SG3 Management's VIR Position: Q4 2021 in Review

SG3 Management sold out of Vir Biotechnology (VIR) in Q4 2021, closing a stake of 81,500 shares — an estimated $3.55M sold.

SG3 Management first reported a position in VIR in Q3 2021 and held it in 1 quarter. The position peaked at $3.55M in Q3 2021. 210 funds tracked by Wall St. Rank hold VIR as of Q4 2021.

SG3 Management reported no remaining Vir Biotechnology position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 81,500 Vir Biotechnology shares in Q4 2021, an estimated $3.55M.
SG3 Management first reported a position in Vir Biotechnology in Q3 2021 and held it in 1 quarter.
SG3 Management's Vir Biotechnology position peaked at $3.55M in Q3 2021.
210 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.